Mark Blumenkranz is a notable inventor based in Menlo Park, California, recognized for his impactful contributions to the field of fluid delivery systems. With a total of two patents to his name, he has demonstrated a commitment to advancing medical technology, particularly in ocular applications.

Latest Patents

His latest patents reflect his innovative approach. The first, titled "Fluid Delivery Alignment System," features a device designed for delivering fluid to the ocular surface. This invention incorporates a self-alignment mechanism, allowing precise fluid delivery to the target area on a user’s eye. The device includes a fluid package with a reservoir and apertures, alongside an actuator configured to eject fluid efficiently. Additionally, the kit includes methods for utilizing these devices in various fluid delivery scenarios.

The second patent, "Piezoelectric Fluid Dispenser," describes a fluid delivery mechanism employing a piezoelectric actuator connected to a preloaded ampoule containing the fluid. This ampoule is crafted from thin-walled thermoplastic material with strategically positioned apertures. The piezoelectric actuator’s oscillations create acoustic pressure cycles in the fluid, enabling the controlled ejection of droplets or streams through the ampoule's walls.

Career Highlights

Blumenkranz is associated with Kedalion Therapeutics, Inc., where he continues to push the boundaries of innovation in medical fluid delivery systems. His work underscores a dedication to improving patient outcomes through technological advancement in healthcare.

Collaborations

Throughout his career, Blumenkranz has collaborated with esteemed colleagues, including Daniel V. Palanker and Ehud Ivri. These partnerships have fostered an environment of creativity and progress, leading to the development of advanced medical devices.

Conclusion

Mark Blumenkranz exemplifies the spirit of innovation within the realm of medical technology. His patents not only enhance fluid delivery mechanisms but also reflect a greater commitment to improving healthcare solutions. His ongoing work at Kedalion Therapeutics signifies a promising future for advancements in ocular fluid delivery systems.

This text is generated by artificial intelligence and may not be accurate.